BSF Enterprise (LSE:BSFA), the biotechnology company developing tissue engineering and bioactive materials, said the US Patent and Trademark Office has issued a Notice of Allowance for a patent covering "Collagen Production".
The application, held by BSF's wholly owned subsidiary 3D Bio-Tissues, protects methods using the bioactive peptide ETSYL, also known as palmitoyl pentapeptide-87, to stimulate collagen production in cells.
A Notice of Allowance confirms the claims have cleared substantive USPTO examination for novelty and inventive step, with formal issuance to follow once the standard fee is paid ahead of a December statutory deadline.
The patent underpins BSF's worldwide exclusive supply and commercialisation agreement with SCHAKAU Managementberatung for ETSYL in cosmetics and luxury beauty, giving that partnership formal US patent protection in what the company calls the largest global market for anti-ageing skincare and bioactive peptide formulations.
The technology originated in 3D Bio-Tissues' tissue-engineering research aimed at accelerating collagen synthesis in lab-grown structures, before finding a commercial route into cosmetic actives.
"Having our core collagen-boosting mechanism formally allowed establishes a robust intellectual property foundation," said Che Connon, chief executive of BSF Enterprise, adding that the US protection "enhances the long-term commercial value of our supply arrangements" with SCHAKAU.
News Intelligence what this means for the company
The US Patent and Trademark Office has issued a Notice of Allowance for BSF Enterprise's ETSYL collagen-boosting peptide, clearing substantive examination and moving toward formal patent issuance once fees are paid by December. This strengthens the IP foundation of the licensing deal with SCHAKAU, which grants that partner worldwide exclusive supply and commercialisation rights in cosmetics and luxury beauty—the company's stated largest global market for anti-ageing skincare.
- SCHAKAU gains formal US patent protection for its exclusive ETSYL commercialisation rights, reducing regulatory and IP risk to the partnership's long-term value.
The patent allowance removes a material IP uncertainty that could have weakened BSF's licensing revenue stream from SCHAKAU. SCHAKAU funds clinical substantiation, regulatory filings, and launch, so BSF captures supply revenue without development capital outlay—a structure now backed by granted US patent protection in the world's largest anti-ageing market.
Insights assembled by AI. Editor-reviewed and grounded in tickstock’s coverage and proprietary knowledge graph.
Content is for informational purposes only, not financial advice.